Tesamorelin reconstitution calculator
- Concentration
- 5 mg/mL
- Doses per vial
- 10
- Weeks (1 dose/wk)
- 10
20 units (0.2 mL) on a 1 mL U-100 syringe: 1 mg from a 10 mg vial + 2 mL water (Tesamorelin).
Dosing table for a 10 mg vial
Syringe units (U-100) for each dose, by how much bacteriostatic water you add.
| Dose | 1 mL water | 2 mL water | 2.5 mL water | 3 mL water |
|---|---|---|---|---|
| 0.5 mg | 5 | 10 | 12.5 | 15 |
| 1 mg | 10 | 20 | 25 | 30 |
| 1.5 mg | 15 | 30 | 37.5 | 45 |
| 2 mg | 20 | 40 | 50 | 60 |
| 2.5 mg | 25 | 50 | 62.5 | 75 |
| 3 mg | 30 | 60 | 75 | 90 |
How the math works
Concentration is the vial's milligrams divided by the water you add. Volume to draw is your dose divided by that concentration. On a U-100 syringe, 1 mL is 100 units, so units = mL × 100.
1 mg ÷ 5 mg/mL = 0.2 mL
0.2 mL × 100 = 20 units
How many units is 1 mg of Tesamorelin?
With a 10 mg vial and 2 mL of bacteriostatic water, 1 mg is 20 units (0.20 mL) on a U-100 syringe. With 1 mL of water it is 10 units. The answer always depends on how much water was added.
How much bacteriostatic water for a 10 mg Tesamorelin vial?
The water only sets the concentration; the amount of Tesamorelin in the vial stays the same. 2 mL makes 5 mg/mL, so 1 mg is 20 units. 2.5 mL makes 4 mg/mL, so the same 1 mg is 25 units. More water makes small doses easier to measure but needs more volume per injection.
How many 1 mg doses are in a 10 mg vial?
10 ÷ 1 = 10, so 10 full doses of 1 mg. Any liquid lost in the needle and vial is not counted.
How much bac water for 10mg tesamorelin?
The water volume is a free choice and only sets the concentration: 1 mL gives 10 mg per mL, 2 mL gives 5 mg per mL and 5 mL gives 2 mg per mL. The Egrifta WR label itself uses 1.3 mL for 11.6 mg.
Calculated from vial mg 10; water m L 1, 2, 5. Formula: 10 / 1 = 10; 10 / 2 = 5; 10 / 5 = 2 mg per mL
How do you reconstitute tesamorelin?
For the approved Egrifta WR product, the label instructs to swirl and not shake after adding the diluent.[3]
Is there a tesamorelin 20mg vial?
The Egrifta SV label describes a 2 mg vial, and the WR label describes a single larger vial; neither label mentions the bigger research-use sizes that people search for.[4]
What is the labelled tesamorelin dose in units?
On a U-100 syringe 0.35 mL (the Egrifta SV dose of 1.4 mg) is 35 units, a strength of 4 mg per mL, while the Egrifta WR dose of 1.28 mg in 0.16 mL is 16 units, a strength of 8 mg per mL. The two are not substitutable.
Calculated from SV dose mg 1.4, volume m L 0.35; WR dose mg 1.28, volume m L 0.16; units per m L 100. Formula: units = volume_mL x 100; mg per mL = dose_mg / volume_mL
Preset doses are round numbers for the arithmetic, not dosing guidance. Vial sizes are the ones most often mentioned for Tesamorelin in community discussions.
Tesamorelin vial strengths on the FDA labels
Egrifta WR is labelled as a single-patient-use vial of 11.6 mg of tesamorelin, supplied with a multiple-dose bottle of bacteriostatic water.[3]
The label sets the mixing volume at 1.3 mL and gives the resulting strength as 8 mg per mL.[3]
The older Egrifta SV is a different product: a 2 mg single-dose vial with 10 mL of sterile water.[4]
The labelled dose of Egrifta WR is a fixed 1.28 mg, not the round-number doses used in the trials below. A research-use vial has no label strength to check against.[3]
At the labelled 8 mg per mL, the labelled 1.28 mg dose is 0.16 mL, which reads as 16 units on a U-100 syringe. A 1 mL U-100 syringe is marked to 100 units, so 1 unit is 0.01 mL.
Calculated from dose mg 1.28; concentration mg per m L 8; u100 units per m L 100. Formula: 1.28 / 8 = 0.16 mL; 0.16 x 100 = 16 units
Trial doses worked through on this calculator
The large 26-week randomized trial in HIV-associated abdominal fat used a fixed amount: 2 mg injected under the skin every day.[5]
A 12-week dose-ranging trial tested both 1 mg and 2 mg once daily against placebo.[6]
A small pilot in people with normal cognition to mild cognitive impairment used 1 mg.[7]
If a 2 mg dose came from a 10 mg research vial mixed with 2 mL, the concentration would be 5 mg per mL and the dose would measure 40 units. Mixed with 1 mL it is 10 mg per mL and 20 units.
Calculated from dose mg 2; vial mg 10; water m L 2, 1. Formula: 10 / 2 = 5 mg/mL; 2 / 5 x 100 = 40 units. 10 / 1 = 10 mg/mL; 2 / 10 x 100 = 20 units
The same 10 mg vial holds 5 doses of 2 mg, so at a once-daily schedule it would be empty after 5 days, well inside the 7-day discard window printed on the Egrifta WR label.
Calculated from vial mg 10; dose mg 2. Formula: 10 / 2 = 5 doses
Where tesamorelin arithmetic goes wrong
The label states that a reconstituted Egrifta WR vial provides daily doses for 7 days, not until empty.[3]
7 doses of 1.28 mg use 8.96 mg of the 11.6 mg in the vial, so about 2.64 mg is not used. Dividing 11.6 by 1.28 to count 9 doses ignores the label discard rule.
Calculated from vial mg 11.6; dose mg 1.28; days 7. Formula: 7 x 1.28 = 8.96 mg; 11.6 - 8.96 = 2.64 mg
The SV and WR labels warn that they are not substitutable, so a unit count worked out for either cannot be carried to the other.[3]
Egrifta SV dose in volume
The Egrifta SV label gives its dose as 1.4 mg, which is 0.35 mL of the reconstituted solution.[4]
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3EGRIFTA WR prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 4EGRIFTA SV prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 5Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 6A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
- 7The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
Found an error? Report a correction.